News

August 17, 2018August 17, 2018

Cancer Cells Can Flood Bloodstream with Protein ‘Warriors’ Against Immune Response, Study Finds

News

Cancer cells release into the bloodstream small vesicles armed with PD-1 ligand (PD-L1) — a protein that suppresses the activation of cancer-fighting immune cells — so as to mute anti-tumor ... Read more

August 15, 2018

New Method Uses Bioinformatics to Monitor Immunotherapy Response to Cancer

News

A newly developed method that combines sequencing with bioinformatics can help monitor the effectiveness of immunotherapy in patients being treated for cancer, according to Johns Hopkins researchers. Their study, “The Mutation-Associated ... Read more

August 14, 2018August 14, 2018

FDA Grants Breakthrough Therapy Designation to Lenvima-Keytruda Combo for Advanced Endometrial Carcinoma

News

The U.S. Food and Drug Administration granted breakthrough therapy designation to an investigational combination of Eisai’s Lenvima (lenvatinib) and Merck‘s Keytruda (pembrolizumab) for the treatment of patients with a subset of advanced endometrial carcinoma. Specifically, the ... Read more

August 10, 2018August 10, 2018

Seattle Children’s Hospital Enrolling Patients with Advanced Solid Tumors for Study of CAR T-cell Immunotherapy

News

Seattle Children’s Hospital is enrolling children and young adults with specific and advanced solid tumors in a Phase 1 clinical trial assessing whether T-cell immunotherapy can treat these abnormal masses ... Read more

August 8, 2018

FDA Grants Fast Track Designation to Galinpepimut-S for Treating Multiple Myeloma

News

Galinpepimut-S, an experimental cancer vaccine developed by SELLAS Life Sciences, was granted fast track designation by the U.S. Food and Drug Administration for the treatment of multiple myeloma. A therapy candidate is put on a fast ... Read more

August 7, 2018August 7, 2018

BioLineRx Initiates Phase 1/2a Trial Testing AGI-134 in Metastatic Solid Tumors

News

A Phase 1/2a clinical trial is seeking patients with metastatic solid tumors who are unfit for surgery to participate in a study of BioLineRx‘s immunotherapy AGI-134. The trial (NCT03593226) is expected to enroll ... Read more

August 3, 2018August 3, 2018

Advaxis to Open Phase 1 Trial of ADXS-503, Potential Immunotherapy for Metastatic NSCLC

News

ADXS-503, an investigational treatment for non-small cell lung cancer that targets mutations in tumor driver genes, will soon move into a first clinical trial in patients, its developer, Advaxis, announced. The Phase ... Read more

August 1, 2018

FDA OKs Phase 1 Trial to Test Celyad’s Donor-derived CAR T-cell Therapy in Colorectal Cancer

News

Celyad will soon begin clinical development of its immunotherapy CYAD-101 (CAR-T NKG2D) and evaluate its potential as a treatment for patients with colorectal cancer that cannot be surgically removed. The first-in-human ... Read more

July 31, 2018July 31, 2018

New IO Therapies Reach Cancer Patients in 4 Months, But Study Warns That Speed May Raise Risks

News

Most patients eligible for cancer immunotherapy start treatment within a few months of the medications’ approval by the U.S. Food and Drug Administration (FDA), a new study reports. The results ... Read more

July 27, 2018July 27, 2018

Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bavencio for Colorectal Cancer

News

Vyriad is expanding its ongoing Phase 1 clinical trial testing Voyager-V1, its lead virotherapy candidate, to include a combination study with PD-L1 inhibitor Bavencio (avelumab) for metastatic colorectal cancer patients. The ... Read more